Wafik S. El-Deiry, Director of Legorreta Cancer Center at Brown University and Chair of the WIN Consortium in Cancer Personalized Medicine, shared a post on LinkedIn:
“Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.”
Title: Homologous recombination deficiency and hemizygosity drive resistance in breast cancer
Authors: Anton Safonov, Minna Lee, David N. Brown, Luca Boscolo Bielo, Miika Mehine, Chaitanya Bandlamudi, Ben O’Leary, Hong Shao, Laia Vicente, Daniel Muldoon, Allen Zhu, Susana Ros, Antonio Marra, Pier Selenica, Ivan Bieche, Bradley Wubbenhorst, Emanuela Ferraro, Laura Courtois, Rania El Botty, Mehnaj Ahmed, Enrico Moiso, Julia Ah-Reum An, Mark T. A. Donoghue, Marie Will, Fresia Pareja, Emily Nizialek, Natalia Lukashchuk, Eleni Sofianopoulou, Yuan Liu, Xin Huang, Colombe Chappey, Anna D. Staniszewska, Dara Ross,
Diana Mandelker, Marc Ladanyi, Nikolaus Schultz, Michael F. Berger, Maurizio Scaltriti, Jorge S. Reis-Filho, Bob T. Li, Kenneth Offit, Larry Norton, Ronglai Shen, Kara N. Maxwell, Fergus Couch, Susan M. Domchek, Elisabetta Marangoni, Sohrab Shah, Mark R. Albertella, Violeta Serra, Britta Weigelt, David B. Solit, Katherine L. Nathanson, Mark E. Robson, Nicholas C. Turner, Sarat Chandarlapaty, Pedram Razavi
Read The Full Article
Other articles about Breast Cancer on OncoDaily.